AbolerIS Pharma Announces First Patient Dosed in Part II of Phase 1 Study of ABO21009, a Novel Anti-CD45RC Antibody, for Rheumatoid Arthritis
PR Newswire —
- ABO21009's unique mechanism of action depletes pathogenic Effector T and B cells while inducing expansion of Regulatory T cells for lasting efficacy, and preserving overall immunity - GOSSELIES, Belgium and NANTES, France, Jan. 8, 2026 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a...